Explore News By Topic


FDA approves enzalutamide for metastatic castration-sensitive prostate cancer

December 16, 2019 – Today the U.S. Food and Drug Administration (FDA) approved a new use for enzalutamide (Xtandi®) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Enzalutamide has previously been FDA-approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded... Read More


Winship study sheds light on immune control of cancer

Issued by: Emory University Woodruff Health Sciences Center New findings could provide doctors with vital clues about how the immune system prevents cancer from recurring. The study from Winship Cancer Institute of Emory University looked at whether immune cells were present in tumor samples removed from patients with kidney and... Read More


The Prostate Cancer Foundation Adds Four New Centers Of Excellence To Serve And Honor Veterans With Prostate Cancer

LOS ANGELES, Calif., Nov. 11, 2019 /PRNewswire/ -- Four new Prostate Cancer Foundation (PCF) Centers of Excellence (COEs) have joined the PCF's dedicated network of centers executing the ambitious mission of improving the care for U.S. Veterans with prostate cancer. With the addition of the new centers, the PCF has established 10 COEs... Read More


Results of the CARD trial: Benefit for patients needing a third-line therapy option

Metastatic castration-resistant prostate cancer (mCRPC) refers to prostate cancer that has spread outside the prostate and no longer responds to traditional androgen deprivation therapy (ADT). Patients have several different treatment options, including second-generation androgen-signaling-targeted inhibitors (ARTA) like abiraterone or enzalutamide, and chemotherapy drugs (docetaxel, cabazitaxel). However, for patients whose disease... Read More


Artificial Intelligence and Prostate Cancer Diagnosis

The field of artificial intelligence (AI) started in the 1950’s in the defense industry, and has evolved over the years. In the 2010s, new computer-based “deep-learning” methods were introduced that significantly accelerated the field. Physician-scientists are using this technology in the medical field to improve diagnostic methods. One such researcher... Read More


Studying the Effects of ADT on Brain Function

Androgen deprivation therapy (ADT) is a primary treatment for prostate cancer, and acts by blocking the production or action of testosterone and other male hormones that activate the androgen receptor (AR). Studies have suggested that ADT may affect cognition and has been associated with the development of Alzheimer’s disease and... Read More


New Precision Medicine Treatment Could Benefit Many Men with Treatment-Resistant Metastatic Prostate Cancer

October 1, 2019.  A study presented yesterday at the 2019 European Society for Medical Oncology (ESMO) Congress reported positive results from a Phase 3 clinical trial testing the PARP-inhibitor olaparib (Lynparza) in patients with metastatic castration-resistant prostate cancer (mCRPC) who have alterations  in certain DNA damage repair (DDR) genes; a... Read More



LOS ANGELES, Calif., September 26, 2019 – The Prostate Cancer Foundation (PCF) today announced a collaboration with Pfizer Global Medical Grants to fund approximately $2 million in research grants through a Competitive Research Grants Program, which  is focused on investigating talazoparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in prostate cancer.... Read More


FDA Approves Apalutamide (Erleada) for the treatment of metastatic hormone-sensitive prostate cancer

September 18, 2019 – Last night the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for the treatment of metastatic hormone-sensitive (aka, “castration-sensitive”) prostate cancer (mHSPC).  Apalutamide has previously received FDA-approval for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). PCF funded the initial synthesis of apalutamide at UCLA... Read More


The Prostate Cancer Foundation Made History by Lighting U.S. Landmarks “Blue” Across All 50 States to Illuminate Prostate Cancer Issue

LOS ANGELES, Calif., September 4, 2019 – For the first time in American history, U.S. landmarks in all 50 states (and the District of Columbia) were lit blue on September 3 to kick-off Prostate Cancer Awareness Month. The Prostate Cancer Foundation’s (PCF) “Light It Blue” campaign is a national effort... Read More